Keratosis pilaris-like eruption secondary to nilotinib in a child

Nilotinib is a new multitargeted tyrosine kinase inhibitor, which is used to treat chronic myelogenous leukemia when intolerance or recurrence to imatinib occurs. We report the case of a 14-year-old patient being treated with nilotinib who developed a keratosis pilaris-like eruption. This cutaneous adverse effect is a rare but increasingly reported side effect of this therapy.

Keywords: BCR-ABL-positive; chronic; leukemia; myelogenous; protein kinase inhibitors.